Author flags UNCY and CING as high-risk penny biotech names with FDA catalysts and asymmetric upside if approvals land.
UNCY — LONG Author sees Unicycive's resubmitted NDA for Oxylanthanum Carbonate as likely to gain FDA approval because the prior CRL was CMC/manufacturing only, not safety or efficacy. If approved, the tiny ~$120M market cap could re-rate toward the $1–4B+ hyperphosphatemia opportunity and bull PTs around $40+. Main risk is binary FDA approval: the setup remains high-risk and gains depend on approval.
approval odds considered high.
CING — LONG Cingulate's CTx-1301 for ADHD has a PDUFA date of 31 May and uses a well-known molecule, lowering clinical risk. A tiny ~$33M market cap could re-rate toward the $20B+ ADHD TAM if once-daily abuse-deterrent execution works; bull PTs range $25–60. Main risk is binary FDA/execution risk: approval is not guaranteed and the stock remains high-risk.
molecule is well-known → lower clinical risk.
This Reddit post, published January 06, 2026, features u/Low-Pollution-262 discussing UNCY, CING. 2 trade ideas extracted by AI with direction and confidence scoring.
Speakers: u/Low-Pollution-262 · Tickers: UNCY, CING